| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/22/2002 | CA2427112A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/21/2002 | EP1233059A1 Influenza viruses with enhanced transcriptional and replicational capacities |
| 08/21/2002 | EP1233058A1 Method of proliferating natural killer cells |
| 08/21/2002 | EP1233023A1 Transcription factor and dna thereof |
| 08/21/2002 | EP1233018A2 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233017A1 Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233016A1 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233013A1 Novel phenylalanine derivatives |
| 08/21/2002 | EP1232758A1 Polynucleotide formulated for improved intracellular transfer |
| 08/21/2002 | EP1232757A1 Remedies for diseases in association with decrease in bone mass |
| 08/21/2002 | EP1232750A1 Non-beta-oxidizable fatty acid analogues and their use for reduction of growth of cancer cells |
| 08/21/2002 | EP1232749A1 Non-beta-oxidizable fatty acid analogues and their uses for inhibition of oxidative modification of low density lipoprotein |
| 08/21/2002 | EP1232748A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 08/21/2002 | EP1232284A1 Genomic polymorphism for predicting therapeutic response |
| 08/21/2002 | EP1232266A2 Polypeptides and nucleic acids encoding same |
| 08/21/2002 | EP1232264A2 Human fgf-21 gene and gene expression products |
| 08/21/2002 | EP1232263A2 Polypeptides and nucleic acids encoding same |
| 08/21/2002 | EP1232257A2 Modular transport systems for molecular substances and production and use thereof |
| 08/21/2002 | EP1232247A2 Modulation of signal transduction |
| 08/21/2002 | EP1232246A1 A human normal counterpart of cd4+ cd56+ cutaneous neoplasm |
| 08/21/2002 | EP1232187A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 08/21/2002 | EP1232186A2 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin |
| 08/21/2002 | EP1232185A2 Methods of inhibiting metastasis |
| 08/21/2002 | EP1232183A2 Peptides having antiangiogenic activity |
| 08/21/2002 | EP1232180A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 08/21/2002 | EP1232179A1 15 human secreted proteins |
| 08/21/2002 | EP1232178A2 Compositions and methods for regulating tumor-associated antigen expression |
| 08/21/2002 | EP1232177A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 08/21/2002 | EP1232176A1 Tumour suppressor factor |
| 08/21/2002 | EP1232174A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 08/21/2002 | EP1232170A1 Antimitotic compounds |
| 08/21/2002 | EP1232168A2 Synthetic lipid-a analogs and uses thereof |
| 08/21/2002 | EP1232153A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 08/21/2002 | EP1232147A1 Triazoles as farnesyl transferase inhibitors |
| 08/21/2002 | EP1232146A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 08/21/2002 | EP1232144A2 Novel il-8 receptor antagonists |
| 08/21/2002 | EP1231984A1 Phorboxazole derivatives for treating cancer |
| 08/21/2002 | EP1231982A2 Use of phthalazine derivatives |
| 08/21/2002 | EP1231944A2 Targeted delivery of therapeutic and diagnostic moieties |
| 08/21/2002 | EP1231942A1 Cobalamin conjugates useful as imaging agents and as antitumor agents |
| 08/21/2002 | EP1231940A1 Stable amorphous amifostine composition, and preparation thereof |
| 08/21/2002 | EP1231939A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231938A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231937A2 Tr3-specific binding agents and methods for their use |
| 08/21/2002 | EP1231923A1 Protease inhibitors |
| 08/21/2002 | EP1231922A1 Protease inhibitors |
| 08/21/2002 | EP1231921A1 Protease inhibitors |
| 08/21/2002 | EP1231919A2 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| 08/21/2002 | EP1231916A2 Use of indirubine derivatives for making medicines |
| 08/21/2002 | EP1231914A2 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 08/21/2002 | EP1231913A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 08/21/2002 | EP1231910A2 Inhibitors of endo-exonuclease activity such as pentamidine for treating cancer |
| 08/21/2002 | EP1231907A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 08/21/2002 | EP1231840A1 Anti-angiogenic cellular agent for cancer therapy |
| 08/21/2002 | EP1124550A4 Methods and compositions for selective cancer chemotherapy |
| 08/21/2002 | EP1053224B1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament |
| 08/21/2002 | EP1041991A4 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha |
| 08/21/2002 | EP0980251B1 Tissue factor for influencing blood vessel formation |
| 08/21/2002 | EP0929308B1 Pharmaceutical composition containing an embryonic extract as an active substance and relative preparation process |
| 08/21/2002 | EP0759757B1 Oral liquid alendronate formulations |
| 08/21/2002 | EP0675715B1 Cell differentiation induction with mevalonate and mevalonolactone derivatives |
| 08/21/2002 | CN1365395A Tenascin-C nucleic acid liqands |
| 08/21/2002 | CN1365356A Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 08/21/2002 | CN1365355A Quinoline derivatives as inhibitors of MEK enzymes |
| 08/21/2002 | CN1365288A Method for detecting and killing epithelial cancer cells |
| 08/21/2002 | CN1365281A Metalloprotease inhibitors |
| 08/21/2002 | CN1364589A Medicine for curing carcinoma of stomach |
| 08/21/2002 | CN1364460A Dibenzo [a, KI] xanthene derivative used as anti-tumor medicine |
| 08/21/2002 | CN1089344C Inhibitor of stem cell proliferation and uses thereof |
| 08/21/2002 | CN1089250C Anti-cancer oral liquid contg. lipolytic enzyme |
| 08/21/2002 | CN1089245C Soy extract, process for its prepn. and pharmaceutical compsn. |
| 08/21/2002 | CN1089244C Chinese patent medicine for treating cancers and unknown toxic swellings (subcutaneous ulcer and carbuncle) and its preparing process |
| 08/21/2002 | CN1089241C Bloody clam or big clam extract with anticancer function |
| 08/21/2002 | CN1089239C Pyrimidine nucleotide precursors of treatment of animal inflammations and tissue damages |
| 08/21/2002 | CN1089237C Compound for use in preparing medium for inhibiting vascular smooth muscle cell migration |
| 08/20/2002 | US6437177 α-hydroxy, -amino, and halo derivatives of β-sulfonyl hydroxamic acids as matrix metallopropteinases inhibitors |
| 08/20/2002 | US6437165 Useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. |
| 08/20/2002 | US6437146 Mesangial proliferative glomerulonephritis |
| 08/20/2002 | US6437137 Naphthyl compounds, intermediates, processes, compositions, and methods |
| 08/20/2002 | US6437128 Cribrostatins 3-5 |
| 08/20/2002 | US6437111 Bone morphogenetic protein-11 (BMP-11) compositions |
| 08/20/2002 | US6437110 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/20/2002 | US6437098 Genetic engineering; anticarcinogenic agents; side effect reduction |
| 08/20/2002 | US6437094 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 08/20/2002 | US6436991 Composition and method containing products extracted from Commiphora sp. for prevention and treatment of abnormal cell growth and proliferation in inflammation, neoplasia and cardiovascular disease |
| 08/20/2002 | US6436977 Dosing regimens for lasofoxifene |
| 08/20/2002 | US6436973 Leukotriene enzyme inhibitors, administered as antiarthritic and antiinflammatory agents; prophylaxis of psoriasis and liver disorders |
| 08/20/2002 | US6436967 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors |
| 08/20/2002 | US6436965 Inhibition of phosphodiesterase; 3-carbocyclic(alkyl)oxy-2-aryl(alkyl)aminocarbonyl-1-aryl(alkyl)indole or azaindole derivatives |
| 08/20/2002 | US6436960 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof |
| 08/20/2002 | US6436951 Camptothecin tetracyclic analogues, preparation, method, applications as medicines and pharmaceutical compositions containing them |
| 08/20/2002 | US6436949 Heterocyclically substituted benzamides and their use |
| 08/20/2002 | US6436945 Substituted O6-benzyl-8-aza-guanines |
| 08/20/2002 | US6436931 Cytotoxic agents comprising taxanes and their therapeutic use |
| 08/20/2002 | US6436929 Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 08/20/2002 | US6436925 Better able to cross membranes; inhibitors of cysteine proteases like calpain i and ii and cathepsin b and l, can thus be used to control diseases associated with an elevated activity of calpain enzymes or cathepsin enzymes |
| 08/20/2002 | US6436923 Compounds and methods for modulation of estrogen receptors |
| 08/20/2002 | US6436913 Use of estramustine phosphate in the treatment of bone metastasis |
| 08/20/2002 | US6436691 Chemical compounds |
| 08/20/2002 | US6436686 Isolated microtubule motor protein having microtubule stimulated adenosine triphosphatase activity and having greater than 90% amino acid sequence identity to specified sequence as measured using sequence comparison algorithm |